Transaction Structure Delivers Immediate Value (Image Credits: Unsplash)
Jupiter, Florida — Ligand Pharmaceuticals announced a definitive agreement on Monday to purchase XOMA Royalty Corporation in an all-cash transaction valued at approximately $739 million.[1][2] The deal offers XOMA shareholders $39 per share plus a contingent value right tied to ongoing litigation proceeds, marking a strategic consolidation in the biotech royalty aggregation space. Both companies specialize in providing non-dilutive funding to drug developers in exchange for future royalties and milestones.[3]
Transaction Structure Delivers Immediate Value
XOMA Royalty common stockholders stand to receive $39.00 per share in cash, a figure that represents a 14% premium to the company’s 30-day volume-weighted average price as of April 24, 2026.[1] This cash portion equates to a total equity value of about $739 million. In addition, each share comes with one non-transferable contingent value right, or CVR, entitling holders to a share of 75% of net proceeds from XOMA’s pending litigation against Janssen Biotech over the commercialization of TREMFYA, a treatment for Crohn’s disease.[2]
XOMA’s Series X Convertible Preferred Stock will convert to common stock before closing, while Series A and Series B Perpetual Preferred Stock face redemption, including all accrued dividends. The boards of both companies unanimously approved the merger agreement. Major shareholders, including entities linked to BVF Partners holding about 21% of common stock – or 44% assuming Series X conversion – entered voting agreements in support.[1] Ligand plans to fund the purchase using existing cash reserves and its revolving credit facility.
Portfolio Synergies Promise Diversified Growth
The acquisition catapults Ligand’s royalty holdings beyond 200 assets, incorporating more than 120 new commercial, clinical, and preclinical-stage programs from XOMA.[3] Among the highlights, seven marketed products join the fold, including Roche’s VABYSMO for eye disease, Day One Pharmaceuticals’ OJEMDA for pediatric low-grade glioma, and Zevra Therapeutics’ MIPLYFFA for Niemann-Pick disease.[1] Late-stage assets nearly double for Ligand, with additions like Takeda’s mezagitamab for immune thrombocytopenia and programs such as osavampator for depression, volixibat for cholestatic pruritus, and OHB-607 for retinopathy of prematurity.
This blend spans ophthalmology, oncology, central nervous system disorders, and rare diseases, cutting across development phases and modalities. Ligand, already a key player with interests in over 100 assets including its Captisol and NITRICIL technologies, gains complementary exposure without operational overhead. XOMA, based in Emeryville, California, built its portfolio by monetizing future economics from licensed therapeutics, aligning closely with Ligand’s model out of Jupiter, Florida.[1]
- VABYSMO (faricimab-svoa) – Roche
- OJEMDA (tovorafenib) – Day One Pharmaceuticals
- MIPLYFFA (arimoclomol) – Zevra Therapeutics
- Mezagitamab – Takeda (Phase 3)
- Osavampator – late-stage CNS
Financial Boost Underpins Raised Outlook
Ligand anticipates the deal will prove immediately accretive to adjusted earnings per share. In response, the company lifted its fiscal 2026 guidance across key metrics. Revenue now projects at $270 million to $310 million, up from $245 million to $285 million, with royalties specifically climbing to $225 million to $250 million from $200 million to $225 million.[1]
Adjusted diluted EPS guidance rose to $8.50 to $9.50 per share, compared to the prior $8.00 to $9.00 range. Captisol sales and contract revenue projections remain steady at $35 million to $40 million and $10 million to $20 million, respectively. Looking ahead, Ligand forecasts an extra $1.50 per share in adjusted EPS accretion for 2027. The transaction may elevate short-term leverage, but strong cash flows from the expanded portfolio mitigate risks.
Market reaction reflected optimism: XOMA shares climbed 6.2% in premarket trading, while Ligand gained 4.6%.[3]
Executives Highlight Strategic Alignment
Todd Davis, CEO of Ligand, emphasized the deal’s transformative potential. “The acquisition of XOMA Royalty presents a compelling opportunity for us to strengthen and diversify our portfolio across all stages of clinical development and accelerate our long-term profitable growth,” he stated. “This acquisition will add seven marketed products and nearly double our portfolio of Phase 2 and 3 assets, which we believe will create significant value for our stockholders, all through a single transaction.”[1]
Owen Hughes, CEO of XOMA Royalty, echoed the sentiment after reviewing alternatives. “After evaluating a broad range of strategic and financing alternatives, we believe combining our diverse portfolio with a company that shares our commitment to helping the biopharmaceutical industry thrive represents the most compelling outcome for XOMA Royalty’s stockholders,” Hughes said. “The structure delivers to our stockholders both the intrinsic value of XOMA’s portfolio today and the optionality associated with our ongoing litigation with Janssen Biotech via the CVR.”[2]
Regulatory Path and Next Steps
Completion remains targeted for the third quarter of 2026, pending XOMA shareholder approval – requiring a majority of voting power – expiration of the Hart-Scott-Rodino antitrust waiting period, and standard closing conditions.[2] No financing contingency applies to Ligand. The merger features a one-step structure, with XOMA becoming a wholly owned subsidiary post a holding company reorganization and CVR spin-off.
This pact underscores a maturing trend among royalty aggregators seeking scale amid biopharma funding challenges. As Ligand integrates XOMA’s assets, investors watch for sustained royalty inflows that could redefine its growth trajectory in a competitive landscape.
